Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Levation Pharma Initiates Phase I/II Clinical Trial of LEV102 for Acquired Blepharoptosis
Details : LEV102 (oxymetazoline) is an adrenergic α1- and α2-agonist and a direct-acting sympathomimetic, causing vasoconstriction of dilated arterioles and reduces blood flow. It is currently being investigated in phase I/II clinical trial for acquired blepharo...
Product Name : LEV102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2023
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Sato Yakuhin Kogyo Co., Ltd
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Details : Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trial...
Product Name : Rhofade
Product Type : Other Small Molecule
Upfront Cash : $5.0 million
December 21, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Sato Yakuhin Kogyo Co., Ltd
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Afrin® (oxymetazoline hydrochloride) provides targeted fast relief, for children who suffer from nasal congestion due to colds or allergies. Afrin® Extra Moisturizing Stuffy Nose Pump Mist, for ages two to six years old unblocks a stuffy nose fast.
Product Name : Afrin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Novan
Deal Size : $51.0 million
Deal Type : Acquisition
Novan Acquires EPI Health, a Specialty Dermatology Company
Details : Acquisition forward integrates Novan with complementary commercial infrastructure to drive commercial launch of SB206, subject to regulatory approval, for the treatment of molluscum contagiosum.
Product Name : Rhofade
Product Type : Other Small Molecule
Upfront Cash : $27.5 million
November 03, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Novan
Deal Size : $51.0 million
Deal Type : Acquisition
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : RVL Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals, Inc.
Details : As another company invested in optimal patient health, RVL Pharmaceuticals offers appropriate patients a nonsurgical solution for acquired ptosis and provides results in as fast as 5 minutes with UPNEEQ (oxymetazoline hydrochloride ophthalmic solution).
Product Name : Upneeq
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 30, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : RVL Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Athyrium Capital
Deal Size : $24.0 million
Deal Type : Private Placement
RVL Pharmaceuticals Plc Announces Insider and Athyrium-Led Financing
Details : The financing reflects in the brand and enhances the financial position as build momentum with the expanded launch of UPNEEQ (oxymetazoline hydrochloride). Provider and patient feedback continue to be positive as UPNEEQ awareness grows.
Product Name : Upneeq
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 08, 2022
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Athyrium Capital
Deal Size : $24.0 million
Deal Type : Private Placement
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Athyrium Capital
Deal Size : Undisclosed
Deal Type : Financing
Details : The financing provides the Company with additional cash to support the commercialization of Upneeq. As a first-in-class treatment for acquired ptosis, Upneeq offers patients and clinicians a convenient non-surgical therapeutic option.
Product Name : Upneeq
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 10, 2021
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Athyrium Capital
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Alora Pharmaceuticals
Deal Size : $170.0 million
Deal Type : Divestment
Details : Osmotica will retain the RVL Pharmaceuticals business focused on ophthalmology and aesthetics, led by its flagship product, UPNEEQ (Oxymetazoline Hydrochloride).
Product Name : Upneeq
Product Type : Other Small Molecule
Upfront Cash : $110.0 million
June 25, 2021
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Alora Pharmaceuticals
Deal Size : $170.0 million
Deal Type : Divestment
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S FDA has approved Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1%, formerly known as RVL-1201, its novel treatment for acquired blepharoptosis, or ptosis, a condition characterized by the abnormal drooping of the upper eyelid that can l...
Product Name : Upneeq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 07, 2020
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : RVL Pharmaceuticals
Deal Size : $89.0 million
Deal Type : Licensing Agreement
Details : Under the agreement Santen will be responsible for further development of RVL-1201 and regulatory approvals as well as commercialization in its licensed territories under the agreement.
Product Name : Upneeq
Product Type : Other Small Molecule
Upfront Cash : $25.0 million
July 28, 2020
Lead Product(s) : Oxymetazoline Hydrochloride
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : RVL Pharmaceuticals
Deal Size : $89.0 million
Deal Type : Licensing Agreement
Reset All
